Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind, placebo-controlled phase 2 trial of sorafenib in FLT3-ITD positive acute myeloid leukemia
2010-018539-16Phase 2Terminated
- Sponsor
- Philipps-Universität Marburg
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Relapse-free survival. Started Jul 2010; status: terminated.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-018539-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018539-16.